Amedeo's Top 20

Amedeo Smart

Independent Medical Education


17 February 2025

Multidisciplinary Journal Club

  1. Li Y, Marks SM, Beeler Asay GR, Winston CA, et al.
    Effectiveness and Cost-Effectiveness of Expanded Targeted Testing and Treatment of Latent Tuberculosis Infection Among the Medicare Population in 2022.
    Ann Intern Med 2025.

  1. Vijiaratnam N, Girges C, Auld G, McComish R, et al.
    Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.
    Lancet 2025.

  2. Dunn JA, Donnelly P, Elbeltagi N, Marshall A, et al.
    Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial.
    Lancet 2025;405:396-407.

  3. Turpin W, Lee SH, Croitoru K.
    Gut Microbiome Signature in Predisease Phase of Inflammatory Bowel Disease: Prediction to Pathogenesis to Prevention.
    Gastroenterology 2025.

  4. Williams ME, Fennema-Notestine C, Bell TR, Lin SJ, et al.
    Neuroimaging Predictors of Cognitive Resilience against Alzheimer's Disease Pathology.
    Ann Neurol 2025.

  1. Turpin AL, Felisatti F, Chauveau L, Haudry S, et al.
    Association Between Lifestyle at Different Life Periods and Brain Integrity in Older Adults.
    Neurology 2025;104:e213347.

  2. Coughlin DG, Shifflett B, Farris CM, Ma Y, et al.
    alpha-Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson Disease.
    Neurology 2025;104:e210279.

  3. Magielski JH, Ruggiero SM, Xian J, Parthasarathy S, et al.
    The clinical and genetic spectrum of paediatric speech and language disorders.
    Brain 2024.

  4. Nzenwa IC, Panossian VS, DeWane MP, Albutt KH, et al.
    Volume Matters: Examining The Management Of Necrotizing Pancreatitis In The United States.
    Ann Surg 2025.

  5. Lamoureux AA, Fisher MJ, Lemelle L, Pfaff E, et al.
    Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions.
    Clin Cancer Res 2025;31:561-572.

  1. Matusevicius M, Saflund M, Balestrino M, Cappellari M, et al.
    Intravenous Thrombolysis in Patients Taking Direct Oral Anticoagulation Treatment Before Stroke Onset: Results from the Safe Implementations of Treatments in Stroke International Stroke Registry.
    Ann Neurol 2025.

  2. Brosius I, Vakaniaki EH, Mukari G, Munganga P, et al.
    Epidemiological and clinical features of mpox during the clade Ib outbreak in South Kivu, Democratic Republic of the Congo: a prospective cohort study.
    Lancet 2025.

  3. Mantzaris I, Goldfinger M, Uriel M, Shastri A, et al.
    Venetoclax plus Daunorubicin and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia: Results of a Phase 1b Study.
    Blood 2025.

  4. Abara WE, Kirkcaldy RD, Bernstein KT, Galloway E, et al.
    Effectiveness of MenB-4C vaccine against gonorrhea: a systematic review and meta-analysis.
    J Infect Dis 2024.

  5. Deza DC, Alcedo J, Lafuente M, Lopez FJ, et al.
    PROBIOTICS PRESCRIBED WITH HELICOBACTER PYLORI ERADICATION THERAPY IN EUROPE: USAGE PATTERN, EFFECTIVENESS, AND SAFETY: Results from the European Registry on Helicobacter pylori Management (Hp-EuReg).
    Am J Gastroenterol 2025.

  1. Roberts JA, Sime FB, Lipman J, Hernandez-Mitre MP, et al.
    Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter pharmacokinetics study for Screening Antifungal Exposure in Intensive Care Units-the SAFE-ICU study.
    Intensive Care Med 2025.

  2. Bernardino RM, van der Kwast T, Fleshner NE.
    Intraductal Carcinoma and Cribriform Pattern in Prostate Cancer: Challenges and Emerging Perspectives.
    Eur Urol 2025.

  3. Rolfsen ML, Wilcox ME, Mart MF, Jackson JC, et al.
    How I Do It: Communicating to Patients and Families about Post Intensive Care Syndrome.
    Chest 2025.

  4. Corboy JR, Fox RJ, Cutter G, Engebretson E, et al.
    DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial.
    Mult Scler 2025;31:159-173.

  5. Agarwal R, Green JB, Heerspink HJL, Mann JFE, et al.
    COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: Baseline clinical characteristics.
    Nephrol Dial Transplant 2025.


more..


Privacy Policy